Role of MicroRNA-133a in Epithelial Ovarian Cancer Pathogenesis and Progression

Overview

Journal Oncol Lett

Specialty Oncology

Date 2014 Jun 20

PMID 24944666

Citations 17

Authors

Jie Luo

Jianhong Zhou

Qi Cheng

Caiyun Zhou

Zhiming Ding

Affiliations

Soon will be listed here.

Abstract

It has been demonstrated that microRNA (miR)-133a is downregulated in a number of human malignancies and is closely associated with the progression of tumors. The present study was conducted to investigate the contribution of miR-133a to the initiation and malignant progression of human epithelial ovarian cancer (EOC). Quantitative polymerase chain reaction was employed to detect the expression of miR-133a in the human EOC OVCAR-3 cell line, normal human ovarian surface epithelial (tsT) cells and 96 tissue samples, including 70 EOC tissues and 26 normal ovarian tissue sections. Additionally, analysis of the correlation between miR-133a levels and clinicopathological characteristics was carried out. The effect of miR-133a on cell viability, apoptosis, invasion and migration was investigated following transfection with miR-133a mimics and negative control small interfering RNA in OVCAR-3 cells. Marked downregulation of miR-133a was observed in the OVCAR-3 cell line and primary tumor samples, and it was found that reduced miR-133a expression significantly correlated with advanced clinical stages, poor histological differentiation and lymph node metastasis. Furthermore, OVCAR-3 cell viability, invasion and migration were significantly inhibited, while cell apoptosis was increased, following transfection of miR-133a mimics. The present study reveals the critical role that miR-133a plays in EOC pathogenesis and development, indicating that it may act as a promising biomarker for predicting EOC progression and as a potential target for gene therapy.

Citing Articles

Granulosa Cells-Related MicroRNAs in Ovarian Diseases: Mechanism, Facts and Perspectives.

Xiao S, Du J, Yuan G, Luo X, Song L Reprod Sci. 2024; 31(12):3635-3650.

PMID: 38594585 DOI: 10.1007/s43032-024-01523-w.

Comprehensive analysis of differentially expressed profiles of mRNA, lncRNA, and miRNA of Yili geese ovary at different egg-laying stages.

Zhao X, Wu Y, Li H, Li J, Yao Y, Cao Y BMC Genomics. 2022; 23(1):607.

PMID: 35986230 PMC: 9392330. DOI: 10.1186/s12864-022-08774-4.

The Roles of MicroRNA-133 in Gynecological Tumors.

Zhou Y, Cheng Z Gynecol Minim Invasive Ther. 2022; 11(2):83-87.

PMID: 35746911 PMC: 9212183. DOI: 10.4103/GMIT.GMIT_79_20.

The Role of microRNAs in Epithelial Ovarian Cancer Metastasis.

Nguyen V, Yue C, Du K, Salem M, OBrien J, Peng C Int J Mol Sci. 2020; 21(19).

PMID: 32993038 PMC: 7583982. DOI: 10.3390/ijms21197093.

Evaluation of Silencing Effect of miR-133a-5p Mimic on TIM-3 Expression in AML (HL-60) Cell Line.

Hojati Z, Ganjalikhani-Hakemi M, Ameri M, Alimohammadi-Jelodar S, Dehbashi M, Mohammad Ganji M Indian J Clin Biochem. 2020; 35(3):359-366.

PMID: 32647415 PMC: 7326904. DOI: 10.1007/s12291-019-00834-z.

References

Clarke-Pearson D . Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009; 361(2):170-7. DOI: 10.1056/NEJMcp0901926. View

Moriya Y, Nohata N, Kinoshita T, Mutallip M, Okamoto T, Yoshida S . Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet. 2011; 57(1):38-45. DOI: 10.1038/jhg.2011.126. View

Kan C, Hahn M, Gard G, Maidens J, Huh J, Marsh D . Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer. 2013; 12:627. PMC: 3542279. DOI: 10.1186/1471-2407-12-627. View

Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y . Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev. 2010; 11(4):905-11. View

Nohata N, Hanazawa T, Kikkawa N, Sakurai D, Sasaki K, Chiyomaru T . Identification of novel molecular targets regulated by tumor suppressive miR-1/miR-133a in maxillary sinus squamous cell carcinoma. Int J Oncol. 2011; 39(5):1099-107. DOI: 10.3892/ijo.2011.1096. View

Lou Y, Cui Z, Wang F, Yang X, Qian J . miR-21 down-regulation promotes apoptosis and inhibits invasion and migration abilities of OVCAR3 cells. Clin Invest Med. 2011; 34(5):E281. DOI: 10.25011/cim.v34i5.15671. View

Flavin R, Smyth P, Barrett C, Russell S, Wen H, Wei J . miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int J Gynecol Cancer. 2009; 19(4):641-7. DOI: 10.1111/IGC.0b013e3181a48cf9. View

Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y . miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2011; 127(12):2804-14. DOI: 10.1002/ijc.25284. View

Rao P, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd C . Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J. 2010; 24(9):3427-37. PMC: 3231107. DOI: 10.1096/fj.09-150698. View

10.

Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

11.

Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N . Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer. 2011; 106(2):405-13. PMC: 3261671. DOI: 10.1038/bjc.2011.462. View

12.

Wong T, Liu X, Ho A, Yuen A, Ng R, Wei W . Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer. 2008; 123(2):251-257. DOI: 10.1002/ijc.23583. View

13.

Fabian M, Sonenberg N . The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol. 2012; 19(6):586-93. DOI: 10.1038/nsmb.2296. View

14.

Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K . The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer. 2011; 104(5):808-18. PMC: 3048214. DOI: 10.1038/bjc.2011.23. View

15.

Sarver A, French A, Borralho P, Thayanithy V, Oberg A, Silverstein K . Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer. 2009; 9:401. PMC: 2787532. DOI: 10.1186/1471-2407-9-401. View

16.

Nohata N, Hanazawa T, Kikkawa N, Mutallip M, Fujimura L, Yoshino H . Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol. 2010; 38(1):209-17. View

17.

Schmittgen T, Livak K . Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. DOI: 10.1038/nprot.2008.73. View

18.

Wu Z, Wang C, Xiang R, Liu X, Ye S, Yang X . Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer. 2012; 12:51. PMC: 3297527. DOI: 10.1186/1471-2407-12-51. View

19.

Alley M, Scudiero D, Monks A, Hursey M, Czerwinski M, Fine D . Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988; 48(3):589-601. View

20.

Yeh Y, Chuang C, Chao K, Wang L . MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α. Int J Cancer. 2013; 133(4):867-78. DOI: 10.1002/ijc.28086. View